Press Resease

Fibromyalgia Therapeutics Market: by Drug Class (Antidepressants [Duloxetine, Milnacipran, and Other Drugs], Antiepileptic’s [Gabapentin, Pregabalin, and Other Drugs], Muscle Relaxants, Analgesics, and Other Drugs), and by Distribution Channel (Hospital Pharmacy, Retail Pharmacy, and Online Pharmacy): Global Industry Perspective, Comprehensive Analysis and Forecast, 2019 - 2025

Published Date: 07-Nov-2019 Category: Healthcare Report Format : PDF Pages: 110 Report Code: ZMR-4996 Status : Published

According to the report, global demand for fibromyalgia therapeutics was valued at approximately USD 2,727.3 million in 2018, and is expected to generate revenue of around USD 3,493.4 million by end of 2025, growing at a CAGR of around 3.6% between 2019 and 2025

Description

The report covers forecast and analysis for the global fibromyalgia therapeutics market. The study provides historic data from 2016 to 2018 along with forecast from 2019 to 2025 based on revenue (USD Million). In-depth secondary research is used to ascertain overall market size, top industry players, top product, industry associations, etc. Macro-economic indicators such as healthcare industry outlook, healthcare spending, research funding, GDP along with company websites, company annual reports, white papers, financial reports and other sources have also been considered to arrive at the indicated market numbers.

Fibromyalgia is a disease that causes muscle pain and exhaustion. In the event of fibromyalgia, psychiatric illnesses are progressively common, and with the growing occurrence rate, post-traumatic stress disorders are also seen. In patients with fibromyalgia, screening for symptoms of post-traumatic stress disorders is also an important component of evaluation process.

Global Fibromyalgia Therapeutics Market

The study provides a decisive view on the fibromyalgia therapeutics market by segmenting the market based on drug class, distribution channel, and regions. All the segments have been analyzed based on present and future trends and the market is estimated from 2019 to 2025. On the basis of drug class, the fibromyalgia therapeutics market is segmented into antidepressants, antiepileptic, muscle relaxants, analgesics, and other drugs. The antidepressant drugs are majorly used for fibromyalgia treatment. These medicines help to comfort the fatigue and pain associated with the disorder.  The antiepileptic drugs segment accounted for the large share in the fibromyalgia therapeutics market in 2018. Gabapentin and Pregabalin are the major antiepileptic drugs prescribed for fibromyalgia treatment.

By distribution channel the fibromyalgia therapeutics market is segmented into hospital pharmacy, online pharmacy, and retail pharmacy. The hospital pharmacy accounted for larger share in the fibromyalgia therapeutics market. The online pharmacy is likely to register high CAGR in the global market. Regional segmentation includes the current and forecast demand for Asia Pacific, North America, Latin America, Europe, and Middle East & Africa with its further bifurcation into major countries.

The study also includes drivers and restraints for the fibromyalgia therapeutics along with the impact they have on the demand over the forecast period. Besides, the report includes the study of opportunities and trends available in the fibromyalgia therapeutics market on global level. It is observed that the increasing incidents of traumatic stress and road accidents are the main driving factor of the therapy industry for fibromyalgia. A research released in the Pain Research and Management Journal discovered that fibromyalgia syndrome followed physical trauma in 2014. It was discovered that 8 percent of people experienced extensive chronic pain in the research, performed with a particular cohort of people engaged in motor car accidents. The research also showed the incidence rate of fibromyalgia in Israel victims of a 15 percent train crash.

The report also provides company market share analysis in order to give a broader view of the key players in the market. Industry insights and information is delivered in the required format. ZMR develops a list of industry players (manufacturers), distributors, retailers and industry experts. Pfizer, Inc., Eli Lilly and Company, Novartis AG, Sun Pharmaceutical Industries Ltd., Allergan Plc, Aptinyx, Inc., Astellas Pharma, Inc., Innovative Med Concepts, Inc., Prismic Pharmaceuticals, Inc., Intec Pharma Ltd., Sanofi, and Bayer AG.

This report segments the global fibromyalgia therapeutics market as follows:

Global Fibromyalgia Therapeutics Market: Drug Class Segment Analysis

  • Antidepressants (Duloxetine, Milnacipran, and Other Drugs)
  • Antiepileptic’s  (Gabapentin, Pregabalin, and Other Drugs)
  • Muscle Relaxants
  • Analgesics
  • Other Drugs

Global Fibromyalgia Therapeutics Market: Distribution Channel Segment

  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy

Global Fibromyalgia Therapeutics Market: Regional Segment Analysis

  • North America
    • U.S.
  • Europe
    • UK
    • France
    • Germany
  • Asia Pacific
    • China
    • Japan
    • India
  • Latin America
    • Brazil
  • Middle East and Africa

Table Of Content

  • Chapter 1. Preface
    • 1.1. Report Description and Scope
    • 1.2. Research Scope
    • 1.3. Research Methodology
      • 1.3.1. Market Research Process
      • 1.3.2. Market Research Methodology
  • Chapter 2. Executive Summary
    • 2.1. Fibromyalgia Therapeutics Market, 2016-2025 (USD Million)
    • 2.2. Fibromyalgia Therapeutics Market: Snapshot
  • Chapter 3. Fibromyalgia Therapeutics Market - Industry Analysis
    • 3.1. Fibromyalgia Therapeutics Market: Market Dynamics
    • 3.2. Market Drivers
      • 3.2.1. Driver 1
      • 3.2.2. Driver 2
    • 3.3. Restraints
      • 3.3.1. Restraint 1
      • 3.3.2. Restraint 2
    • 3.4. Opportunity
      • 3.4.1. Government funding and support
    • 3.5. Porter's Five Forces Analysis
    • 3.6. Market Attractiveness Analysis
      • 3.6.1. Market attractiveness analysis By Drug Class
      • 3.6.2. Market attractiveness analysis By Distribution Channel
      • 3.6.3. Market attractiveness analysis by Region
  • Chapter 4. Fibromyalgia Therapeutics Market- Competitive Landscape
    • 4.1. Company market share analysis
      • 4.1.1. Global Fibromyalgia Therapeutics Market: company market share, 2018
    • 4.2. Strategic development
      • 4.2.1. Acquisitions & mergers
      • 4.2.2. New Drug Class launches
      • 4.2.3. Agreements, partnerships, collaborations and joint ventures
      • 4.2.4. Research and development and Regional expansion
    • 4.3. Price trend analysis
  • Chapter 5. Global Fibromyalgia Therapeutics Market - By Drug Class Analysis
    • 5.1. Global Fibromyalgia Therapeutics Market overview: By Drug Class
      • 5.1.1. Global Fibromyalgia Therapeutics Marketshare, By Drug Class,2018 and 2025
    • 5.2. Antidepressants (Duloxetine, Milnacipran, and Other Drugs)
      • 5.2.1. Global Fibromyalgia Therapeutics Market by Antidepressants (Duloxetine, Milnacipran, and Other Drugs), 2016-2025 (USD Million)
    • 5.3. Antiepileptic's (Gabapentin, Pregabalin, and Other Drugs)
      • 5.3.1. Global Fibromyalgia Therapeutics Market by Antiepileptic's (Gabapentin, Pregabalin, and Other Drugs), 2016-2025 (USD Million)
    • 5.4. Muscle Relaxants
      • 5.4.1. Global Fibromyalgia Therapeutics Market by Muscle Relaxants, 2016-2025 (USD Million)
    • 5.5. Analgesics
      • 5.5.1. Global Fibromyalgia Therapeutics Market by Analgesics, 2016-2025 (USD Million)
    • 5.6. Others
      • 5.6.1. Global Fibromyalgia Therapeutics Marketby others, 2016-2025 (USD Million)
  • Chapter 6. Global Fibromyalgia Therapeutics Market -Distribution Channel Analysis
    • 6.1. Global Fibromyalgia Therapeutics Market overview: By Distribution Channel
      • 6.1.1. Global Fibromyalgia Therapeutics Market share, By Distribution Channel, 2018 and 2025
    • 6.2. Hospital Pharmacy
      • 6.2.1. Global Fibromyalgia Therapeutics Market By Hospital Pharmacy, 2016-2025 (USD Million)
    • 6.3. Retail Pharmacy
      • 6.3.1. Global Fibromyalgia Therapeutics MarketBy Retail Pharmacy, 2016-2025 (USD Million)
    • 6.4. Online Pharmacy
      • 6.4.1. Global Fibromyalgia Therapeutics Market By Online Pharmacy, 2016-2025 (USD Million)
  • Chapter 7. Global Fibromyalgia Therapeutics Market - Regional Analysis
    • 7.1. Global Fibromyalgia Therapeutics Market overview: by Region
      • 7.1.1. Global Fibromyalgia Therapeutics Marketshare, by Region, 2018 and 2025
    • 7.2. North America
      • 7.2.1. North America Fibromyalgia Therapeutics Market, 2016-2025 (USD Million)
      • 7.2.2. North America Fibromyalgia Therapeutics Market revenue, By Drug Class,2016-2025 (USD Million)
      • 7.2.3. North America Fibromyalgia Therapeutics Market revenue, By Distribution Channel, 2016-2025 (USD Million)
      • 7.2.4. The U.S.
        • 7.2.4.1. The U.S.Fibromyalgia Therapeutics Marketrevenue, By Drug Class,2016-2025 (USD Million)
        • 7.2.4.2. The U.S.Fibromyalgia Therapeutics Market revenue, By Distribution Channel, 2016-2025 (USD Million)
      • 7.2.5. Rest of North America
        • 7.2.5.1. Rest of North America Fibromyalgia Therapeutics Market revenue, By Drug Class,2016-2025 (USD Million)
        • 7.2.5.2. Rest of North America Fibromyalgia Therapeutics Marketrevenue, By Distribution Channel, 2016-2025 (USD Million)
    • 7.3. Europe
      • 7.3.1. Europe Fibromyalgia Therapeutics Market, 2016-2025 (USD Million)
      • 7.3.2. Europe Fibromyalgia Therapeutics Market revenue, By Drug Class,2016-2025 (USD Million)
      • 7.3.3. Europe Fibromyalgia Therapeutics Market revenue, By Distribution Channel, 2016-2025 (USD Million)
      • 7.3.4. UK
        • 7.3.4.1. U.K.Fibromyalgia Therapeutics Marketrevenue, By Drug Class,2016-2025 (USD Million)
        • 7.3.4.2. U.K.Fibromyalgia Therapeutics Market revenue, By Distribution Channel, 2016-2025 (USD Million)
      • 7.3.5. France
        • 7.3.5.1. France Fibromyalgia Therapeutics Marketrevenue, By Drug Class,2016-2025 (USD Million)
        • 7.3.5.2. France Fibromyalgia Therapeutics Marketrevenue, By Distribution Channel, 2016-2025 (USD Million)
      • 7.3.6. Germany
        • 7.3.6.1. Germany Fibromyalgia Therapeutics Marketrevenue, By Drug Class,2016-2025 (USD Million)
        • 7.3.6.2. Germany Fibromyalgia Therapeutics Market revenue, By Distribution Channel, 2016-2025 (USD Million)
      • 7.3.7. Rest of Europe
        • 7.3.7.1. Rest of EuropeFibromyalgia Therapeutics Marketrevenue, By Drug Class,2016-2025 (USD Million)
        • 7.3.7.2. Rest of EuropeFibromyalgia Therapeutics Market revenue, By Distribution Channel, 2016-2025 (USD Million)
    • 7.4. Asia Pacific
      • 7.4.1. Asia Pacific Fibromyalgia Therapeutics Market, 2016-2025 (USD Million)
      • 7.4.2. Asia Pacific Fibromyalgia Therapeutics Marketrevenue, By Drug Class,2016-2025 (USD Million)
      • 7.4.3. Asia Pacific Fibromyalgia Therapeutics Market revenue, By Distribution Channel, 2016-2025 (USD Million)
      • 7.4.4. China
        • 7.4.4.1. China Fibromyalgia Therapeutics Market revenue, By Drug Class,2016-2025 (USD Million)
        • 7.4.4.2. China Fibromyalgia Therapeutics Marketrevenue, By Distribution Channel, 2016-2025 (USD Million)
      • 7.4.5. Japan
        • 7.4.5.1. Japan Fibromyalgia Therapeutics Market revenue, By Drug Class,2016-2025 (USD Million)
        • 7.4.5.2. Japan Fibromyalgia Therapeutics Marketrevenue, By Distribution Channel, 2016-2025 (USD Million)
      • 7.4.6. India
        • 7.4.6.1. India Fibromyalgia Therapeutics Market revenue, By Drug Class,2016-2025 (USD Million)
        • 7.4.6.2. India Fibromyalgia Therapeutics Market revenue, By Distribution Channel, 2016-2025 (USD Million)
      • 7.4.7. Rest of Asia Pacific
        • 7.4.7.1. Rest of Asia Pacific Fibromyalgia Therapeutics Marketrevenue, By Drug Class,2016-2025 (USD Million)
        • 7.4.7.2. Rest of Asia Pacific Fibromyalgia Therapeutics Market revenue, By Distribution Channel, 2016-2025 (USD Million)
    • 7.5. Latin America
      • 7.5.1. Latin America Fibromyalgia Therapeutics Market, 2016-2025 (USD Million)
      • 7.5.2. Latin America Fibromyalgia Therapeutics Marketrevenue, By Drug Class,2016-2025 (USD Million)
      • 7.5.3. Latin America Fibromyalgia Therapeutics Marketrevenue, By Distribution Channel, 2016-2025 (USD Million)
      • 7.5.4. Brazil
        • 7.5.4.1. Brazil Fibromyalgia Therapeutics Marketrevenue, By Drug Class,2016-2025 (USD Million)
        • 7.5.4.2. Brazil Fibromyalgia Therapeutics Marketrevenue, By Distribution Channel, 2016-2025 (USD Million)
      • 7.5.5. Rest of LatinAmerica
        • 7.5.5.1. Rest of LatinAmerica Fibromyalgia Therapeutics Market revenue, By Drug Class,2016-2025 (USD Million)
        • 7.5.5.2. Rest of LatinAmerica Fibromyalgia Therapeutics Market revenue, By Distribution Channel, 2016-2025 (USD Million)
    • 7.6. The Middle East and Africa
      • 7.6.1. The Middle East and Africa Fibromyalgia Therapeutics Market, 2016-2025 (USD Million)
      • 7.6.2. The Middle East and Africa Fibromyalgia Therapeutics Market revenue, By Drug Class,2016-2025 (USD Million)
      • 7.6.3. The Middle East and Africa Fibromyalgia Therapeutics Marketrevenue, By Distribution Channel, 2016-2025 (USD Million)
  • Chapter 8. Company Profiles
    • 8.1. Pfizer, Inc.
      • 8.1.1. Overview
      • 8.1.2. Financials
      • 8.1.3. Drug Class Portfolio
      • 8.1.4. Business Strategy
      • 8.1.5. Recent Developments
    • 8.2. Eli Lilly and Company
      • 8.2.1. Overview
      • 8.2.2. Financials
      • 8.2.3. Drug Class Portfolio
      • 8.2.4. Business Strategy
      • 8.2.5. Recent Developments
    • 8.3. Novartis AG
      • 8.3.1. Overview
      • 8.3.2. Financials
      • 8.3.3. Drug Class Portfolio
      • 8.3.4. Business Strategy
      • 8.3.5. Recent Developments
    • 8.4. Sun Pharmaceutical Industries Ltd.
      • 8.4.1. Overview
      • 8.4.2. Financials
      • 8.4.3. Drug Class Portfolio
      • 8.4.4. Business Strategy
      • 8.4.5. Recent Developments
    • 8.5. Allergan Plc
      • 8.5.1. Overview
      • 8.5.2. Financials
      • 8.5.3. Drug Class Portfolio
      • 8.5.4. Business Strategy
      • 8.5.5. Recent Development
    • 8.6. Aptinyx, Inc
      • 8.6.1. Overview
      • 8.6.2. Financials
      • 8.6.3. Drug Class Portfolio
      • 8.6.4. Business Strategy
      • 8.6.5. Recent Development
    • 8.7. Astellas Pharma, Inc.
      • 8.7.1. Overview
      • 8.7.2. Financials
      • 8.7.3. Drug Class Portfolio
      • 8.7.4. Business Strategy
      • 8.7.5. Recent Development
    • 8.8. Innovative Med Concepts, Inc.
      • 8.8.1. Overview
      • 8.8.2. Financials
      • 8.8.3. Drug Class Portfolio
      • 8.8.4. Business Strategy
      • 8.8.5. Recent Development
    • 8.9. Prismic Pharmaceuticals, Inc.
      • 8.9.1. Overview
      • 8.9.2. Financials
      • 8.9.3. Drug Class Portfolio
      • 8.9.4. Business Strategy
      • 8.9.5. Recent Development
    • 8.10. Intec Pharma Ltd.
      • 8.10.1. Overview
      • 8.10.2. Financials
      • 8.10.3. Drug Class Portfolio
      • 8.10.4. Business Strategy
      • 8.10.5. Recent Development

Methodology

}